Gastroesophageal Junction Adenocarcinoma
📧 Sign up to get email alerts when something new happens for Gastroesophageal Junction Adenocarcinoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2018-03-02Clinical Trial Update: The FLOT Regimen Conversion Therapy of Adenocarcinoma of the Stomach / Gastroesophageal [Phase 2]
A Phase 2 clinical trial update for conversion therapy using the FLOT regimen in adenocarcinoma of the stomach and gastroesophageal junction…
-
CLINICAL_TRIALS trial_result · 2017-03-29Clinical Trial Update: MLN0264 in Previously Treated Asian Participants With Advanced Gastrointestinal Carcinoma or Metastatic or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Guanylyl Cyclase C [Phase 1]
Phase 1 trial update of MLN0264 in previously treated Asian patients with advanced gastrointestinal carcinoma, including gastric and gastroe…
-
CLINICAL_TRIALS trial_result · 2016-02-09Clinical Trial Update: First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma [Phase 3]
Amgen's Phase 3 trial evaluating rilotumumab for MET-positive gastric/GEJ adenocarcinoma was terminated, indicating the study did not procee…
-
CLINICAL_TRIALS research · 2015-06-08Clinical Trial Update: Preoperative Concurrent Chemoradiotherapy for Locally Advanced Gastroesophageal Junction or Upper Gastric Adenocarcinoma [Phase 2, Phase 3]
This document reports an update on a Phase 2/Phase 3 clinical trial evaluating preoperative concurrent chemoradiotherapy for locally advance…
-
CLINICAL_TRIALS trial_result · 2015-06-03Clinical Trial Update: Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer [Phase 2]
This document reports the results update of a Phase 2 trial comparing paclitaxel with or without cixutumumab as second-line therapy for meta…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2015-05-05Clinical Trial Update: Gastric Microperfusion in Patients Undergoing Gastroesophageal Resections
The update reports the completion of a clinical trial evaluating gastric microperfusion in patients undergoing gastroesophageal resections.
-
CLINICAL_TRIALS trial_result · 2015-03-11Clinical Trial Update: Efficacy and Safety of Panitumumab Combined With Docetaxel and Cisplatin as a First-line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma [Phase 2]
Phase 2 trial evaluating the efficacy and safety of combining panitumumab with docetaxel and cisplatin as first-line therapy for advanced ga…
-
CLINICAL_TRIALS research · 2014-12-02Clinical Trial Update: Study of MBP-426 in Patients With Second Line Gastric, Gastroesophageal, or Esophageal Adenocarcinoma [Phase 1, Phase 2]
Clinical trial update on MBP-426 for second-line gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, and esophageal adenocarci…
-
CLINICAL_TRIALS research · 2014-07-18Clinical Trial Update: Intergroup Trial of Adjuvant Chemotherapy in Adenocarcinoma of the Stomach [Phase 3]
Phase 3 intergroup trial evaluating adjuvant chemotherapy for stomach and gastroesophageal junction adenocarcinoma has completed.
-
CLINICAL_TRIALS trial_result · 2014-05-07Clinical Trial Update: Phase 2 Study of AMG 386 (20060439) in Combination With Cisplatin & Capecitabine in Subjects With Metastatic Gastric, Gastroesophageal Junction, or Distal Esophageal Adenocarcinoma [Phase 2]
This Phase 2 trial evaluated trebananib (AMG 386) in combination with cisplatin and capecitabine for metastatic gastric, gastroesophageal ju…
-
FDA approval · 2014-04-21FDA Approved: CYRAMZA — Original Application (Eli Lilly and Company)
The FDA approved the original application for ramucirumab (CYRAMZA) by Eli Lilly for metastatic gastric or gastroesophageal junction adenoca…
-
CLINICAL_TRIALS trial_result · 2013-10-08Clinical Trial Update: 3-AP Plus Cisplatin in Treating Patients With Recurrent or Metastatic Adenocarcinoma of the Esophagus or Gastroesophageal Junction [Phase 2]
This update reports the completion of a Phase 2 trial evaluating 3-AP (Triapine) plus cisplatin in patients with recurrent or metastatic ade…
-
CLINICAL_TRIALS trial_result · 2013-09-30Clinical Trial Update: Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery [Phase 1]
Phase 1 trial evaluating MK-2206 (AKT inhibitor) with lapatinib and trastuzumab in unresectable locally advanced or metastatic HER2-positive…
-
CLINICAL_TRIALS trial_result · 2013-08-07Clinical Trial Update: Symptom Control With or Without Docetaxel in Treating Patients With Relapsed Esophageal Cancer or Stomach Cancer [Phase 3]
A Phase 3 trial evaluated symptom control with docetaxel versus no docetaxel in relapsed esophageal cancer or gastric/gastroesophageal junct…
-
CLINICAL_TRIALS trial_result · 2013-06-21Clinical Trial Update: A Study of BMS-833923 With Cisplatin and Capecitabine in Inoperable, Metastatic Gastric, Gastroesophageal, or Esophageal Adenocarcinomas [Phase 1]
Phase 1 study of the BMS-833923 investigational agent in combination with cisplatin and capecitabine in patients with inoperable, metastatic…
-
CLINICAL_TRIALS trial_result · 2012-11-09Clinical Trial Update: Study of Oxaliplatin and Sorafenib Combination to Treat Gastric Cancer Relapsed After a Cisplatin Based Treatment [Phase 2]
Phase 2 trial evaluating the combination of oxaliplatin and sorafenib for advanced or metastatic gastric cancer or gastroesophageal junction…
-
CLINICAL_TRIALS research · 2012-03-15Clinical Trial Update: Tesetaxel as Second-line Therapy for Patients With Advanced Gastric Cancer [Phase 2]
Phase 2 clinical trial evaluating tesetaxel as second-line therapy for advanced gastric cancer, including gastric and gastroesophageal junct…
-
CLINICAL_TRIALS trial_result · 2012-02-14Clinical Trial Update: Bortezomib in Treating Patients With Unresectable or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma [Phase 2]
This clinical trial update reports on a Phase 2 study of bortezomib for unresectable or metastatic gastric cancer or gastroesophageal juncti…
-
CLINICAL_TRIALS research · 2008-10-21Clinical Trial Update: Phase II Study of Neoadjuvant Taxotere, Cisplatin, and 5-Fluorouracil in Patients With Gastric or Gastroesophageal Junction Adenocarcinoma [Phase 2]
Phase II neoadjuvant trial of docetaxel (Taxotere), cisplatin, and 5-fluorouracil for gastric or gastroesophageal junction adenocarcinoma; n…